Clinical Trial Update: To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV [Phase 1]

View source ↗

Summary

Phase 1 clinical trial comparing VIR-1388 to placebo in adults without HIV to assess safety, reactogenicity, and immunogenicity. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• VIR-1388

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV I Infection | Phase 1 | Status: COMPLETED